| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Wayne Huey-Herng Sheu | Q89111214 |
| Kun Ho Yoon | Q89368209 | ||
| P2093 | author name string | Chaicharn Deerochanawong | |
| Andrea Luk | |||
| Ketut Suastika | |||
| Ambrish Mithal | |||
| Siew Pheng Chan | |||
| Chin Meng Khoo | |||
| Bien J Matawaran | |||
| Juliana Chan | |||
| Ji Linong | |||
| Huu Man Nguyen | |||
| P2860 | cites work | Ectopic fat and insulin resistance: pathophysiology and effect of diet and lifestyle interventions | Q21285128 |
| Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus | Q22241140 | ||
| Metformin monotherapy for type 2 diabetes mellitus | Q24246552 | ||
| The role of fatty acids in insulin resistance | Q26785440 | ||
| Metabolic syndrome and kidney disease: a systematic review and meta-analysis | Q26863240 | ||
| GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients | Q28276621 | ||
| Effect of anti-obesity drug on cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials | Q28480564 | ||
| Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies | Q29614505 | ||
| Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013 | Q29616834 | ||
| Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial | Q29619886 | ||
| Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy | Q29620534 | ||
| Health Effects of Overweight and Obesity in 195 Countries over 25 Years | Q30402965 | ||
| Weight loss prevents urinary incontinence in women with type 2 diabetes: results from the Look AHEAD trial | Q30539603 | ||
| Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes | Q30548796 | ||
| Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial | Q30651606 | ||
| A comparison of risk factors for mortality from heart failure in Asian and non-Asian populations: an overview of individual participant data from 32 prospective cohorts from the Asia-Pacific Region | Q30828094 | ||
| Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials | Q31105792 | ||
| Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group compar | Q33612741 | ||
| Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial | Q33835558 | ||
| A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials | Q33874163 | ||
| A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study | Q33888204 | ||
| Long-term safety and efficacy of tofogliflozin add-on to insulin in patients with type 2 diabetes: results from a 52-week, multicenter, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS). | Q48279607 | ||
| Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial. | Q48333756 | ||
| Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus | Q48353746 | ||
| Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period | Q49963630 | ||
| Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes | Q49963693 | ||
| Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: A randomized controlled trial. | Q50035752 | ||
| Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week, open-label, phase IV study. | Q51246665 | ||
| Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. | Q51304272 | ||
| Efficacy and safety of empagliflozin monotherapy for 52 weeks in Japanese patients with type 2 diabetes: a randomized, double-blind, parallel-group study. | Q51305217 | ||
| Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study. | Q51319263 | ||
| Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial. | Q51320301 | ||
| Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise. | Q51321207 | ||
| Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. | Q51329266 | ||
| Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. | Q51348266 | ||
| Metabolic syndrome and the risk of ischemic heart disease and stroke among Japanese men and women. | Q51473217 | ||
| Appropriate waist circumference cutoff points for central obesity in Korean adults. | Q51497292 | ||
| Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice. | Q51561479 | ||
| CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. | Q51707689 | ||
| Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study). | Q51744128 | ||
| Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy. | Q53128290 | ||
| Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment. | Q55386487 | ||
| Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | Q56979722 | ||
| Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms | Q57150764 | ||
| Body mass index and cardiovascular disease in the Asia-Pacific Region: an overview of 33 cohorts involving 310 000 participants | Q57265839 | ||
| Measures of Abdominal Adiposity and the Risk of Stroke | Q57605696 | ||
| C-Reactive Protein and Cerebral Small-Vessel Disease | Q57781994 | ||
| Obesity and Type 2 Diabetes: What Can Be Unified and What Needs to Be Individualized? | Q58036996 | ||
| 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults | Q61985181 | ||
| Adverse Effect Profile and Effectiveness of Sodium Glucose Co-transporter 2 Inhibitors (SGLT2i) - A Prospective Real-world Setting Study | Q64294876 | ||
| Central obesity and risk of cardiovascular disease in the Asia Pacific Region | Q79892212 | ||
| Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus | Q86932366 | ||
| Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial) | Q89080794 | ||
| Comparison of pancreatic volume and fat amount linked with glucose homeostasis between healthy Caucasians and Koreans | Q89208553 | ||
| Use of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: An Asian perspective and expert recommendations | Q91544396 | ||
| Diabetes Fact Sheets in Korea, 2018: An Appraisal of Current Status | Q92141984 | ||
| 2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea | Q92807729 | ||
| Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes | Q92980564 | ||
| Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomized cont | Q93146539 | ||
| Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis | Q34031108 | ||
| Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus | Q34407893 | ||
| Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes | Q34457919 | ||
| Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | Q34673134 | ||
| Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study | Q34726376 | ||
| Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis | Q34985373 | ||
| SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials | Q35181821 | ||
| Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study. | Q35192198 | ||
| Long-term follow-up after bariatric surgery: a systematic review. | Q35237039 | ||
| One-year changes in symptoms of depression and weight in overweight/obese individuals with type 2 diabetes in the Look AHEAD study | Q35819788 | ||
| Asian women have greater abdominal and visceral adiposity than Caucasian women with similar body mass index | Q35825660 | ||
| Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus | Q35879325 | ||
| Lifestyle change and mobility in obese adults with type 2 diabetes | Q35919090 | ||
| Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition | Q35973288 | ||
| Intensive lifestyle intervention improves physical function among obese adults with knee pain: findings from the Look AHEAD trial | Q36126490 | ||
| Obesity and diabetic kidney disease | Q36515043 | ||
| International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries | Q36777590 | ||
| Why might South Asians be so susceptible to central obesity and its atherogenic consequences? The adipose tissue overflow hypothesis | Q36825515 | ||
| Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial. | Q36843902 | ||
| Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India | Q36867463 | ||
| Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. | Q36964821 | ||
| Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus | Q37018165 | ||
| Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period | Q37060860 | ||
| Impact of a weight management program on health-related quality of life in overweight adults with type 2 diabetes | Q37250961 | ||
| Abdominal obesity is associated with microalbuminuria and an elevated cardiovascular risk profile in patients with hypertension | Q37262554 | ||
| Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients | Q37302700 | ||
| Standards of care for type 2 diabetes in China. | Q37412792 | ||
| Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates | Q37456313 | ||
| Impact of the 8-week Administration of Tofogliflozin for Glycemic Control and Body Composition in Japanese Patients with Type 2 Diabetes Mellitus | Q37521103 | ||
| Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients | Q37524302 | ||
| Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study | Q37532069 | ||
| Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study | Q37679243 | ||
| Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment | Q37873715 | ||
| Sleep apnoea and metabolic dysfunction | Q38133503 | ||
| Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes | Q38204541 | ||
| Effect of orlistat on glycaemic control in overweight and obese patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials | Q38582254 | ||
| Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes | Q38729780 | ||
| AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY. | Q38843101 | ||
| Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. | Q38912082 | ||
| Diuretic Action of Sodium-Glucose Cotransporter 2 Inhibitors and Its Importance in the Management of Heart Failure | Q38947399 | ||
| Efficacy and safety of dapagliflozin in Asian patients: A pooled analysis. | Q39393777 | ||
| The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels | Q39629318 | ||
| Comprehensive risk assessments of diabetic patients from seven Asian countries: The Joint Asia Diabetes Evaluation (JADE) program | Q39983936 | ||
| Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial | Q40266818 | ||
| Safety and Effectiveness of Tofogliflozin in Elderly Japanese Patients with Type 2 Diabetes Mellitus: a Post-Marketing Study (J-STEP/EL Study). | Q40363925 | ||
| Efficacy and safety of dapagliflozin over 1 year as add-on to insulin therapy in Japanese patients with type 2 diabetes: the DAISY (Dapagliflozin Added to patients under InSulin therapY) trial | Q40405896 | ||
| Hypertension, Obesity, Diabetes, and Heart Failure-Free Survival: The Cardiovascular Disease Lifetime Risk Pooling Project | Q40446172 | ||
| Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study | Q40606871 | ||
| Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial | Q40901927 | ||
| SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice. | Q41084455 | ||
| Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. | Q41234175 | ||
| Ipragliflozin Reduces Epicardial Fat Accumulation in Non-Obese Type 2 Diabetic Patients with Visceral Obesity: A Pilot Study | Q41259429 | ||
| Comparison of Combined Tofogliflozin and Glargine, Tofogliflozin Added to Insulin, and Insulin Dose-Increase Therapy in Uncontrolled Type 2 Diabetes | Q41277849 | ||
| Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea | Q41759692 | ||
| Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes | Q42718201 | ||
| Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial | Q42732735 | ||
| Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes | Q43100917 | ||
| Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study | Q43165555 | ||
| Relationship of abdominal obesity with cardiovascular disease, diabetes and hyperlipidaemia in Spain | Q43260778 | ||
| Commentary: Why are South Asians susceptible to central obesity?--the El Niño hypothesis | Q44128167 | ||
| Obesity and kidney disease in type 1 and 2 diabetes: an analysis of the National Diabetes Audit | Q44154005 | ||
| Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events | Q44216708 | ||
| A central body fat distribution is related to renal function impairment, even in lean subjects | Q44383378 | ||
| Repaglinide versus nateglinide monotherapy: a randomized, multicenter study | Q44909493 | ||
| Body mass index, diabetes, and C-reactive protein among U.S. adults | Q46780760 | ||
| Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes. | Q47148933 | ||
| The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis. | Q47175811 | ||
| Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin | Q47187857 | ||
| Impact of Canagliflozin Treatment on Health-Related Quality of Life among People with Type 2 Diabetes Mellitus: A Pooled Analysis of Patient-Reported Outcomes from Randomized Controlled Trials | Q47192734 | ||
| A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus. | Q47374718 | ||
| Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice: interim results of the STELLA-LONG TERM post-marketing surveillance study | Q47398293 | ||
| CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY. | Q47556600 | ||
| Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes | Q47996942 | ||
| Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52-week, open-label, | Q48147721 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P433 | issue | 1 | |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | 11-32 | |
| P577 | publication date | 2020-02-01 | |
| P1433 | published in | Diabetes & metabolism journal | Q26842420 |
| P1476 | title | Use of SGLT-2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Abdominal Obesity: An Asian Perspective and Expert Recommendations | |
| P478 | volume | 44 |
Search more.